glp-1 drugs pharmaceutical companies news 2025 Market Trends and Global Forecasts Report 2025: A GLP-1 Receptor Agonist Market Growth

Phentermine was designed as a short-term intervention

It should be noted that Figure 2 is a simplified representation of the overall approach recommended by the ADA/EASD and includes only recommendations up to the point of dual antihyperglycemic therapy

The action of GIP on CVD in pre-clinical studies is also uncertain

Specifically, prolonged GLP-1RA administration (13 years or longer) has been associated with elevated thyroid cancer risk in certain populations [4], while high concentrations of liraglutide (100 nM) have been demonstrated to promote breast cancer progression via the NOX4/ROS/VEGF signaling pathway [18]

Understanding these contrasts helps patients and clinicians decide which approach delivers true, lasting change rather than short-lived control

Semaglutide 2.4 mg, beyond robust weight reduction and improvements in surrogate markers of CVD, such as lipids and glucose, is now associated with benefits for hard CV outcomes CV death, nonfatal MI and nonfatal stroke. Additionally, while presenting cardiometabolic outcomes for retatrutide, Jastreboff said participants who received the 12 mg dose also experienced a mean 40% reduction in triglyceride levels and a mean 22% reduction in LDL cholesterol at 48 weeks, in addition to reductions in HbA1c and blood pressure